$5 COVID-19 Test: Abbott’s New Price & Details
- Abbott Labs secured emergency FDA authorization for its BinaxNOW COVID-19 Ag Card, a rapid antigen test delivering results in 15 minutes.
- Assistant Secretary for Health, previously called the test a "game-changer."
- The company anticipates producing 50 million tests each month by october, making the COVID-19 test widely accessible. The BinaxNOW COVID-19 test will cost $5 and includes a free...
The FDA has authorized Abbott’s new rapid COVID-19 antigen test, a pivotal advancement providing results in just 15 minutes. The game-changing BinaxNOW test, priced at only $5, utilizes a convenient nasal swab, similar to flu tests, and is poised for mass production—50 million tests monthly by October. those testing negative via this swift COVID-19 test can promptly access a date-stamped health pass through a free mobile app. Experts hail this as a critical tool in curbing virus spread. News Directory 3 provides further insights into this evolving landscape. Discover what’s next for rapid, affordable testing solutions.
Abbott’s Rapid COVID-19 Antigen Test Receives FDA Approval
Abbott Labs secured emergency FDA authorization for its BinaxNOW COVID-19 Ag Card, a rapid antigen test delivering results in 15 minutes. The COVID-19 test,about the size of a credit card,uses a nasal swab,similar to flu tests,to detect the virus.
brett Giroir, U.S. Assistant Secretary for Health, previously called the test a “game-changer.”
The company anticipates producing 50 million tests each month by october, making the COVID-19 test widely accessible. The BinaxNOW COVID-19 test will cost $5 and includes a free mobile app. Those testing negative can display a temporary, date-stamped health pass, renewed with each new test.
Joseph Petrosino, a virology professor at Baylor Collage of Medicine, welcomed the Abbott COVID-19 test, noting its potential to provide quick, reliable testing to millions. He said this would help isolate infectious individuals,curbing the virus’s spread.
while antigen tests, like Abbott’s, are less reliable than PCR tests that detect the virus’s genetic material, they offer speed and affordability. PCR tests have faced supply chain issues and lab backlogs, delaying results.
What’s next
The BinaxNOW COVID-19 Ag Card is the fourth antigen test to recieve emergency use authorization from the FDA. Widespread availability of rapid COVID-19 testing could considerably impact public health strategies.